THE EFFECT OF A NEW ORAL HYPOGLYCEMIC DRUG, CS-045, ON GLUCOSE-TOLERANCE AND SERUM-LIPIDS IN NONOBESE JAPANESE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A PILOT-STUDY

This study examined the effects of a new oral hypoglycemic drug, CS-04 5, on glucose tolerance and serum lipids in 10 nonobese patients with non-insulin-dependent diabetes mellitus (NIDDM). Plasma glucose levels before and at 2, 3, 4, 6, 8, 10, 15, 20, and 30 minutes after adminis tration of the intravenous glucose tolerance test (IVGTT) were signifi cantly (P < 0.05) decreased after administration of CS-045 (400 mg/d) for 8 weeks. However, no significant changes in plasma glucose levels were noted at points measured from 45 to 180 minutes after administrat ion of the drug. Plasma immunoreactive insulin (IRI) levels at the 15 minute-point during the IVGTT were significantly (P < 0.05) decreased after administration of CS-045, but there were no significant changes at any other point before or during the test after administration of t he drug. Area under the curve of plasma glucose and IRI at each point in time of the IVGTT was significantly (P < 0.05) decreased after admi nistration of CS-045. Levels of serum total cholesterol, low-density l ipoprotein cholesterol, triglyceride, and free fatty acid levels were significantly (P < 0.05) decreased and high-density lipoprotein choles terol was significantly (P < 0.05) increased after administration of d rug. These results indicate that CS-045 is an effective oral hypoglyce mic agent that improves glucose tolerance and abnormal serum lipids le vels in nonobese NIDDM patients.